Plazomicin
Daten werden ergänzt – meist innerhalb einer Minute fertig
Grundinformationen
- CAS
1154757-24-0- Standard-SMILES
CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O- InChIKey
IYDYFVUFSPQPPV-PEXOCOHZSA-N- Summenformel
- C25H48N6O10
- Durchschnittliche Molmasse
- 592,691 g/mol
- Monoisotopische Masse
- 592,34319174
Namen und Bezeichner
- Bevorzugter Name
- Plazomicin
- Englischer Name
- Plazomicin
- Summenformel
- C25H48N6O10
- Molmasse
- 592.68
Namen und Synonyme
ACHN 490PlazoMicinPlazomicin APISisomicin Impurity 10IYDYFVUFSPQPPV-BPUQVFSTSA-NPirimicarb Impurity 9 (Ethirimol)O-2-AMino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)aMino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-Methyl-3-(MethylaMino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-aMino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptaMineD-Streptamine, O-2-amino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)amino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-
Datenbank-Bezeichner
- CAS
1154757-24-0- PubChem CID
- 42613186
- DTXSID
DTXSID001031303- ChEMBL
CHEMBL1650559- UNII
- LYO9XZ250J
- Nikkaji
- J3.052.262A
Eigenschaften
Physikochemische Eigenschaften
- Schmelzpunkt
- 185 °C · >185°C (dec.)
- Siedepunkt
- 896.4 · 896.4±65.0 °C(Predicted)
- Dichte
- 1.4 · 1.40±0.1 g/cm3(Predicted)
- storage temp.
- -20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
- Löslichkeit
- Water (Slightly)
- Aggregatzustand
- Solid
- pka
- 13.11 · 13.11±0.20(Predicted)
- Farbe
- Pale Yellow
Chemie und Industrie
Anwendungen
BeschreibungPlazomicin (PLZ) is a novel aminoglycoside approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTI, including acute pyelonephritis) in adults due to multidrug-resistant carbapenem-resistant Enterobacterales (CRE) or extended-spectrum beta-lactamase (ESBL) producing bacteria. Despite the FDA Black Box Warning for aminoglycoside class effects, PLZ exhibited a favourable safety profile with decreased adverse effects in the largest in-human trials. In vitro, activity of PLZ, in comparison with that of other aminoglycosides, was found to be excellent, with 92.3% to 98.0% overall susceptibility in Enterobacterales, including CRE. Recently, PLZ was also shown to be active against certain multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens for which limited treatment options are left[1-2].
Anbieter23 Anbieter
凯试(上海)科技有限公司021-50135380 · [email protected]
Zhejiang J&C Biological Technology Co.,Limited+1-2135480471 · [email protected]
武汉丰泰威远科技有限公司027-87465837 19945049750 · [email protected]
深圳振强药物研发有限公司+86-0755-66853366 +86-13670046396 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
北京秦岭医药科技有限公司010-61241352 18901327973 · [email protected]
安耐吉化学&3A（安徽泽升科技股份有限公司）400-0056266 · [email protected]
浙江珲达生物科技有限公司0571-89903022 18679456698 · [email protected]
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…